StockData
Ascendis Pharma A/S logo

Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)

Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –

Ascendis Pharma A/S free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Ascendis Pharma A/S's free cash flow for the twelve months ending Sep 30, 2024 was -€262.44M. For fiscal 2023 it was -€469.80M. The highest annual figure on record is -€44.51M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-€469.80M–
FY2022Dec 31, 2022-€510.19M–
FY2021Dec 31, 2021-€441.35M–
FY2020Dec 31, 2020-€291.41M–
FY2019Dec 31, 2019-€181.10M–
FY2018Dec 31, 2018-€141.45M–
FY2017Dec 31, 2017-€96.04M–
FY2016Dec 31, 2016-€60.85M–
FY2015Dec 31, 2015-€44.51M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024-€56.60M–
Q2 FY2024Jun 30, 2024-€61.65M–
Q1 FY2024Mar 31, 2024-€101.78M–
Q4 FY2023Dec 31, 2023-€42.41M–
Q3 FY2023Sep 30, 2023-€125.70M–
Q2 FY2023Jun 30, 2023-€153.57M–
Q1 FY2023Mar 31, 2023-€148.13M–
Q4 FY2022Dec 31, 2022-€145.47M–
Q3 FY2022Sep 30, 2022-€102.00M–
Q2 FY2022Jun 30, 2022-€128.12M–
Q1 FY2022Mar 31, 2022-€134.61M–
Q4 FY2021Dec 31, 2021-€128.11M–
Q3 FY2021Sep 30, 2021-€108.82M–
Q2 FY2021Jun 30, 2021-€118.78M–
Q1 FY2021Mar 31, 2021-€85.64M–
Q4 FY2020Dec 31, 2020-€94.60M–
Q3 FY2020Sep 30, 2020-€62.69M–
Q2 FY2020Jun 30, 2020-€61.20M–
Q1 FY2020Mar 31, 2020-€72.93M–
Q4 FY2019Dec 31, 2019-€50.37M–
Q3 FY2019Sep 30, 2019-€61.20M–
Q2 FY2019Jun 30, 2019-€6.21M–
Q1 FY2019Mar 31, 2019-€63.33M–
Q4 FY2018Dec 31, 2018-€36.62M–
Q3 FY2018Sep 30, 2018-€47.54M–
Q2 FY2018Jun 30, 2018-€20.45M–
Q1 FY2018Mar 31, 2018-€36.84M–
Q4 FY2017Dec 31, 2017-€24.39M–
Q3 FY2017Sep 30, 2017-€25.90M–
Q2 FY2017Jun 30, 2017-€24.13M–
Q1 FY2017Mar 31, 2017-€21.63M–

More Ascendis Pharma A/S figures

See a number that looks wrong?